OND | Multiple sclerosis | |||
---|---|---|---|---|
All | SP/PP | RR | ||
9HPT, nine hole PEG test; AI, ambulation index; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; N/A, not applicable; NfHSMI34, NfH detected with SMI34 antibody; NfHSMI35, NfH detected with SMI35 antibody; OND, other neurological diseases; PP, primary progressive; RR, relapsing remitting; SP, secondary progressive. | ||||
Baseline | ||||
Number | 271/119 | 29 | 19 | 10 |
NfHSMI35 (pg/ml) | 260 (0–3990) | 78 (80–610) | 95 (25–163) | 53 (11–139) |
p<0.001 | ||||
NfHSMI34 (pg/ml) | 10 (0–12000) | 9 (7–13) | 11 (7–14) | 7 (5–9) |
p<0.05 | ||||
Ratio | 1.52 (0.36–5.49) | 1.5 (0.6–5.4) | 1.7 (0.6–5.8) | 1 (0.42–3.5) |
EDSS | N/A | 3.25 (2.0–6.5) | 6.0 (3.0–7.0) | 1.5 (1.0–2.0) |
p<0.001 | ||||
AI | N/A | 2 (1–7) | 6 (2–8) | 1 (1–1) |
p<0.01 | ||||
9HPT | N/A | 24.5 (20.5–28.5) | 26.0 (24.0–30.0) | 20.0 (18.0–22.0) |
p<0.01 | ||||
Follow up | ||||
Number | – | 29 | 19 | 10 |
NfHSMI35 (pg/ml) | N/A | 113 (0–178) | 129 (0–209) | 0 (0–120) |
p<0.05 | ||||
NfHSMI34 (pg/ml) | N/A | 50 (9–129) | 30 (10–114) | 51 (3–120) |
Ratio | N/A | 3 (1–10.1) | 3 (1–10.1) | 5 (0–10) |
ΔNfHSMI35 (pg/ml) | N/A | 4 (−59–98) | 82 (−38–115) | −49 (−38–104) |
ΔNfHSMI34 (pg/ml) | N/A | 37 (−1–123) | 22 (−3–95) | 51 (1–112) |
EDSS | N/A | 4.5 (3.5–6.0) | 5.5 (4.0–6.5) | 3.0 (2.5–4.0) |
p<0.01 | ||||
AI | N/A | 2 (2–5) | 4 (2–7) | 1 (1–2) |
p<0.01 | ||||
9HPT | N/A | 23.5 (20.0–28.5) | 24.5 (21.5–31.0) | 20.0 (18.0–21.0) |
p<0.05 |